Want to see JP:206A full AI Analyst Report?
Top Page
PRISM BioLab Co. LTD
(206A)
Select Model
Select Model
Rating:51Neutral
Price Target:
¥163.00
▲(1.88% Upside)
Action:Reiterated
Date:08/29/26
The score is held back primarily by weak financial performance—persistent losses and deteriorating free cash flow—despite strong recent revenue growth and a debt-free balance sheet. Technicals are comparatively supportive with a clear uptrend and positive momentum, but valuation is constrained by negative earnings and no stated dividend yield.
Positive Factors
Strong Revenue Growth
Sharp recent revenue growth indicates that PRISM BioLab is expanding the commercial or partnering activity around its drug-discovery programs. If sustained, this broader revenue base could improve operating leverage and provide more resources to advance its pipeline over the next several quarters.
Negative Factors
Persistent Deep Losses
Persistent, deeply negative EBIT and net income show that recent revenue expansion has not yet translated into a sustainable profit engine. Continued losses can constrain internally funded research, increase reliance on future financing or partnerships, and delay evidence of durable operating leverage.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Revenue Growth
Sharp recent revenue growth indicates that PRISM BioLab is expanding the commercial or partnering activity around its drug-discovery programs. If sustained, this broader revenue base could improve operating leverage and provide more resources to advance its pipeline over the next several quarters.
Read all positive factors
PRISM BioLab Co. LTD (206A) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥6.21B
Dividend YieldN/A
Average Volume (3M)94.70K
Price to Earnings (P/E)―
Beta (1Y)0.84
Revenue Growth84.23%
EPS Growth33.14%
CountryJP
Employees35
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-6.56
Shares Outstanding36,989,000
10 Day Avg. Volume102,240
30 Day Avg. Volume94,696
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)2.27
Price to Sales (P/S)9.06
P/FCF Ratio-4.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
PRISM BioLab Co. LTD Business Overview & Revenue Model
Company Description
PRISM BioLab Co., LTD. engages in the research and development of pharmaceuticals using its proprietary drug discovery platform, PepMetics Technology. The company's technology focuses on creating peptide mimetic small molecules designed to mimic α...
How the Company Makes Money
PRISM BioLab primarily makes money through partnering and licensing its drug discovery programs and related intellectual property to larger pharmaceutical or biotechnology companies. Revenue typically comes from (1) upfront payments received when ...
PRISM BioLab Co. LTD Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 |
|---|---|---|---|---|
Income Statement | ||||
| Total Revenue | 677.33M | 305.62M | 112.93M | 554.40M |
| Gross Profit | 269.76M | 160.54M | 80.31M | 535.14M |
| EBITDA | -831.28M | -1.05B | -488.13M | 67.89M |
| Net Income | -833.70M | -1.05B | -526.91M | 72.96M |
Balance Sheet | ||||
| Total Assets | 3.09B | 4.53B | 1.21B | 1.74B |
| Cash, Cash Equivalents and Short-Term Investments | 2.92B | 4.39B | 1.13B | 1.69B |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 376.86M | 1.03B | 63.41M | 65.23M |
| Stockholders Equity | 2.71B | 3.50B | 1.15B | 1.67B |
Cash Flow | ||||
| Free Cash Flow | -1.53B | -61.55M | -548.40M | 97.25M |
| Operating Cash Flow | -1.47B | 150.14M | -513.81M | 102.96M |
| Investing Cash Flow | -69.01M | -244.19M | -40.38M | -7.87M |
| Financing Cash Flow | 33.59M | 3.37B | 0.00 | 110.87M |
PRISM BioLab Co. LTD Technical Analysis
Negative
160.00
Price Trends
161.08
Positive
157.69
Positive
170.96
Negative
Market Momentum
2.79
Positive
43.59
Neutral
21.40
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:206A, the sentiment is Negative. The current price of 160 is below the 20-day moving average (MA) of 171.65, below the 50-day MA of 161.08, and below the 200-day MA of 170.96, indicating a neutral trend. The MACD of 2.79 indicates Positive momentum. The RSI at 43.59 is Neutral, neither overbought nor oversold. The STOCH value of 21.40 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:206A.
PRISM BioLab Co. LTD Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | ¥6.43B | 63.98 | ― | 1.57% | -9.94% | ― | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
51 Neutral | ¥6.21B | -6.83 | ― | ― | 84.23% | 33.14% | |
46 Neutral | ¥33.18B | -72.88 | ― | ― | 3.43% | -53.59% | |
44 Neutral | ¥14.55B | -29.41 | ― | ― | -18.71% | -246.54% | |
44 Neutral | ¥8.96B | -7.67 | ― | ― | -56.16% | 3.12% | |
40 Underperform | ¥14.98B | -6.06 | ― | ― | ― | 4.68% |
* General Sector Average
JP:206A
PRISM BioLab Co. LTD
162.00
-9.00
-5.26%
JP:4599
StemRIM Inc.
180.00
-125.00
-40.98%
JP:4880
CellSource Co., Ltd.
318.00
-265.14
-45.47%
JP:4978
ReproCELL Inc.
135.00
-57.00
-29.69%
JP:7774
Japan Tissue Engineering Co., Ltd.
790.00
288.00
57.37%
JP:7776
CellSeed Inc.
222.00
-249.00
-52.87%
PRISM BioLab Co. LTD Corporate Events
PRISM BioLab’s Revenue Rises but Losses Deepen and Equity Shrinks
Aug 14, 2026
PRISM BioLab reported non-consolidated revenue of ¥369 million for the nine months to June 30, 2026, up 19.4% year on year, but continued to post operating and net losses, with net income at a loss of ¥845 million and basic earnings per ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.